CT/X-Ray Contrast Media

Founded in 1992, BeijingBeiluPharmaceuticalsCompanyLimited is mainly engaged in the research & development, production and sales of pharmaceutical products. It is high-tech innovation company with core competence in the Contrast Media domestic. It has around 650 employees with 0.82 Bn/￥ revenue in 2019. Beiluprovides complete Contrast Media products Include ct contrast medium, mri contrast medium, gadopentetate dimeglumine,etc, and it is the leading manufacturer in the Contrast Media field in China. It is one of the 1st batches of listed enterprises in GEM of SZSE (Ticker: 300016.SZ) in China.

The main component of CT/X-ray Contrast Media is iodine based contrast agents. The Iodinated radiocontrast Media is a colorless, transparent, slightly viscous liquid. At present, the contrast agents used in ct can be mainly divided into ionic and non iodinated contrast media, according to the osmotic pressure can be divided into hypertonic, isotonic and hypotonic. Currently, non-ionic, isotonic or hypotonic, types of contrast media in ct are used clinically. When the contrast medium used in ct scan is injected, 97% of the contrast media can be directly excreted from the kidneys within 1 day.

Evaluate patient benefits/risks before use

History of allergies: Patients who have previously experienced moderate to severe ct contrast dye reactions to iodine containing contrast medium agents or patients with a history of allergies requiring treatment are at an increased risk of having an allergic reaction to CT dye.

Kidney function: iodinated contrast agents can cause acute kidney injury, and patients should be evaluated for related risks before the surgery.

Combination medication: drugs that may increase the risk of adverse reactions to iodinated contrast agents: neuroleptics and antidepressants, interleukin-2, beta-blockers, metformin.

Situations where iodinated contrast agents should be used with caution: lung and heart diseases, catecholamine secreting tumours, pregnant and lactating women, myeloma and macroglobulinemia, myasthenia gravis, homocystinuria.

Contraindication: uncured patients with hyperthyroidism.

Dose limit for iodinated contrast agents
On the premise of satisfying imaging/diagnosis, the minimum dose of iodinated contrast agents should be used.

For low-risk patients, the total dose of types of contrast agents had better be controlled within 300 ~ 400 ml.

Maximum dose of iodinated radiocontrast dye

Method I *: 5 ml × body weight (kg)/serum creatinine (mg/dl) (not more than 300 ml) [refer to Cigarroa calculation formula]

Method II: 3.7 times creatinine clearance [according to 2011 ACCF/AHAUA/NSTEMI Treatment Guidelines]

For those with severe renal insufficiency, try to choose an imaging method that does not require iodine-based contrast agents or a non-imaging method that can provide sufficient diagnostic information.

Avoid repeated use of the diagnostic dose of an iodinated contrast agent in a short period of time. If repeated use is indeed necessary, it is recommended that the interval between two MRI contrast agent applications be ≥14 days.

Other precautions for the use of iodinated contrast agents

Preheating: Before using an iodinated contrast agent, it is recommended to heat the contrast agent to 37 °C and place it in a thermostat.

Hydration: It is recommended to hydrate patients within 6 to 12 hours before using an iodinated contrast agent to within 24 hours after use. Hydration method: Intra-arterial drug users are advised to receive intravenous rehydration and oral rehydration concomitantly, and oral rehydration is recommended for intravenous drug users.

Stay and observation: After the injection of the iodine-based contrast media, the patient needs to stay and be observed for 30 minutes before leaving the examination room.

Establish an emergency channel: Establish an emergency rapid support mechanism for the rescue of adverse reactions caused by iodinated contrast agents with the emergency room or other clinical related departments to ensure that after an adverse reaction occurs, clinicians can promptly rush to the rescue scene for rescue if necessary.

Prevention and Management of Vascular Extravasation of Iodinated Contrast Agents
Prevention

Choose appropriate blood vessels for venipuncture and operate carefully; when using a high-pressure syringe, choose a puncture needle and catheter that match the injection flow rate; properly fix the puncture needle; communicate with the patient and get cooperation.

Management
Mild extravasation: Most injuries are minor and need no treatment. However, the patient should be instructed to keep observing. If the extravasation worsens, the patient should seek medical attention in time. For individuals with significant pain, common cold and hydropathic compresses can be given locally.

Moderate and severe extravasation: ① raise the affected limb to promote blood return. ② Use 50% magnesium sulfate moisturizing cold compress in the beginning, and after 24-hours change to magnesium sulfate moisturizing hot compress, or use mucopolysaccharide ointment for topical application, or use 0.05% dexamethasone for local hydropathic compress. ③ Those with severe contrast agent extravasation should be given oral dexamethasone 5 mg/time tid for 3 consecutive days on the basis of topical drug use. ④ If necessary, consult a clinician for medication.

Other supplier products

	Diethylenetriaminepentaacetic acid (DTPA)	DTPA Diethylenetriaminepentaacetic Acid(DTPA) CAS No.: 67-43-6 Molecular formula: C₁₄H₂₃N₃O₁₀ Molecular weight: 393.35 Quality standard...
	Calcobutrol	CAS No.: Molecular formula: C18H32CaN4O9 Molecular weight: 488.5461 Quality standard: CP Characteristics: White or off-white powder ...
	Diethylenetriaminepentaacetic acid (DTPA)	CAS No.: 67-43-6 Molecular formula: C₁₄H₂₃N₃O₁₀ Molecular weight: 393.35 Quality standard: CP Characteristics: White powder Content (HPLC): &g...
	Gadopentetate Dimeglumine Injection/API	Founded in 1992, BeijingBeiluPharmaceuticalsCompanyLimitedis mainly engaged in the research & development, production and sales of pharmaceutic...
	Iopamidol Injection	Iopamidol Injectionis the second-generation non-ionic iodinated Contrast Media launched in the global market. In 2015, Beilufirstly launched and li...

供应产品

Same products

	Sulfachloropyrazine Sodium Soluble Powder 30% 500g	卖方: Hebei Shengxue Dacheng Pharmaceutical Co., Ltd.	Trade Name: Shengxue QiulingCommon Name: Sulfachloropyrazine Sodium Soluble PowderMain Ingredient...
	Carbasalate Calcium Soluble Powder	卖方: Hebei Shengxue Dacheng Pharmaceutical Co., Ltd.	Brand Name: Shengxue ResunGeneric Name: Carbasalate Calcium Soluble PowderActive Ingredient: Carb...
	Tylvalosin Tartrate Premix	卖方: Hebei Shengxue Dacheng Pharmaceutical Co., Ltd.	Brand name:Shengxue TaikesCommon name:Tylvalosin tartrate premixMain ingredient:Tylvalosin tartra...
	Ferric Ammonium Citrate Effervescent Granules	卖方: 北京北陆药业股份有限公司	Ferric Ammonium Citrate Effervescent Granules was launched in 2004. It is an oral magnetic resona...
	Diethylenetriaminepentaacetic acid (DTPA)	卖方: 北京北陆药业股份有限公司	Diethylenetriaminepentaaceticacid (DTPA) CAS No.: 67-43-6 Molecular formula: C₁₄H₂₃N₃O₁₀ M...